model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Claude-4.5-Sonnet,protocolSection.identificationModule.nctId,TP,TP,NCT00195091,NCT00195091,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.orgStudyIdInfo.type,EV,EV,,<UNKNOWN>,,,,OrgStudyIdType,protocolSection.identificationModule.orgStudyIdInfo.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.orgStudyIdInfo.link,EV,EV,,,,,,OrgStudyIdLink,protocolSection.identificationModule.orgStudyIdInfo.link,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.secondaryIdInfos[1].id,EV,EV,,18-023,,,,SecondaryId,protocolSection.identificationModule.secondaryIdInfos.id,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.secondaryIdInfos[1].type,EV,EV,,OTHER,,,,SecondaryIdType,protocolSection.identificationModule.secondaryIdInfos.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.secondaryIdInfos[1].domain,EV,EV,,Memorial Sloan Kettering Cancer Center,,,,SecondaryIdDomain,protocolSection.identificationModule.secondaryIdInfos.domain,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.secondaryIdInfos[0].link,EV,EV,,,,,,SecondaryIdLink,protocolSection.identificationModule.secondaryIdInfos.link,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.secondaryIdInfos[1].link,EV,EV,,,,,,SecondaryIdLink,protocolSection.identificationModule.secondaryIdInfos.link,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.briefTitle,TP,TP,Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer,Phase II clinical trial of tetrathiomolybdate (TM) in high-risk breast cancer patients,True,0.96,success,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.officialTitle,TP,TP,A Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer at Moderate to High Risk of Recurrence,Phase II clinical trial of tetrathiomolybdate (TM) in high-risk breast cancer patients,True,0.96,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.acronym,EV,EV,,,,,,Acronym,protocolSection.identificationModule.acronym,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.briefSummary,TP,FP,"Patients with moderate to high risk primary breast cancer (Stage II with more than 4 lymph nodes involved with cancer) III or Stage IV (without evidence of disease) will take tetrathiomolybdate (TM) pills for two years.

The objectives of the study are to:

* Assess the safety and tolerability of tetrathiomolybdate in patients with breast cancer at high risk of tumor recurrence.
* Observe the disease-free survival of patients in this trial.
* Conduct background scientific experiments on tumor tissue and blood of patients in this study","This study investigates the mechanisms by which copper depletion impacts metastasis in triple-negative breast cancer (TNBC). The orally bioavailable copper chelating agent tetrathiomolybdate (TM) has shown significant survival benefits in high-risk TNBC patients. Using two independent TNBC models, the researchers identified a discrete subpopulation of highly metastatic SOX2/OCT4+ cells within primary tumors that exhibit elevated intracellular copper levels and marked sensitivity to TM. Global proteomic and metabolomic profiling revealed that TM-mediated inactivation of mitochondrial Complex IV is the primary metabolic defect in the SOX2/OCT4+ cell population. The study also identifies the AMPK/mTORC1 energy sensor pathway as an important downstream mediator, and shows that AMPK inhibition rescues TM-mediated loss of invasion. Loss of the mitochondria-specific copper chaperone COX17 restricts copper deficiency to mitochondria and phenocopies TM-mediated alterations. These findings identify a copper-metabolism-metastasis axis with potential to enrich patient populations in next-generation therapeutic trials.",False,0.36,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.detailedDescription,TP,FP,"Patients with moderate to high risk primary breast cancer -Stage III, Triple negative (T= 4 cm N0, any N+), Stage IV (without evidence of disease) will take tetrathiomolydbate (TM) pills for two years.

Extension study 1 - If patients are shown to be copper depleted, they are given the option to continue to receive TM for an additional 2 years.

Extension study 2 - Open to patients who are stage 4 NED, 10 involved lymph nodes or triple negative molecular subtype and candidates will continue for months 49-72.

Extension study 3 - Open to patients who are stage 4 NED receiving a benefit from TM. These subjects can continue receiving TM for 73-96 months.

Extension study 4 - Open to patients who are stage 4 NED receiving a benefit from TM. These subject can continue receiving TM for 97-120 months.","Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER−), progesterone receptor (PR−), and HER2 overexpression (HER2−). TNBC accounts for 10-15% of all breast cancers and is associated with poor outcomes due to lack of response to current targeted therapies and higher rates of metastasis. Copper serves as a cofactor for metalloenzymes that contribute to malignant progression. The copper chelating agent tetrathiomolybdate (TM) has been associated with significant survival benefit in high-risk TNBC patients. A phase II clinical trial (NCT00195091) showed that TM was safe and well-tolerated, with event-free survival (EFS) of 72% and overall survival (OS) of 84% at median follow-up of 6.3 years. The TNBC cohort with stage 4 disease showed EFS of 69% after 2 years, a striking finding compared to median EFS and OS of less than 8 months and 12 months, respectively, in other trials.

This study uses in vivo lineage tracing of the metastatic compartment in primary breast tumors, together with proteomic and metabolomic profiling, to provide a direct link between copper-mediated metabolic reprogramming and metastasis in TNBC. Using the SOX2/OCT4-GFP promoter reporter system, the researchers lineage traced a subpopulation of SOX2+OCT4+ cancer cells within the primary tumor that exhibit stem cell phenotypes and enhanced potential for metastasis. These cells showed higher basal intracellular copper levels compared to reporter-negative cells and exhibited marked sensitivity to TM-mediated copper depletion.

Quantitative protein abundance profiling using liquid chromatography-mass spectrometry (LC-MS) identified multiple subunits of mitochondrial Complex IV that were specifically downregulated after TM treatment in reporter-positive cells. Gene ontology analysis revealed enrichment of pathways involved in the mitochondrial electron transport chain (ETC). TM-mediated copper depletion led to degradation of Complex IV subunits and resulted in significant reduction (>60%) in oxidation of cytochrome c. Extracellular flux analysis showed that reporter-positive cells exhibited higher rates of oxygen consumption compared to reporter-negative cells, and TM treatment resulted in dramatic reduction in basal respiration and ATP-linked respiration in reporter-positive cells.

To confirm that mitochondrial copper depletion was responsible for the observed phenotypes, the researchers targeted COX17, a mitochondria-specific copper chaperone that transports copper to Complex IV. COX17 knockdown reduced oxygen consumption, ATP-linked respiration, invasion, and lung metastases, phenocopying TM-mediated alterations. TM-mediated reduction in oxidative phosphorylation (OXPHOS) decreased ATP production and triggered activation of the AMPK-mTORC1 pathway. AMPK inhibition rescued TM-mediated loss of invasion, demonstrating that AMPK is a downstream mediator of TM-mediated invasion defects.

These findings identify a copper-metabolism-metastasis axis and highlight its potential to be developed as a next-generation therapeutic approach for high-risk TNBC patients. The study provides mechanistic insights that may facilitate patient selection for future TM trials and advance TM into larger randomized phase II trials.",False,0.56,success,DetailedDescription,protocolSection.descriptionModule.detailedDescription,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.conditions,TP,FP,['Breast Cancer'],"['Triple Negative Breast Cancer', 'Metastatic Breast Cancer', 'Breast Neoplasms']",False,0.0,disjoint,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.keywords,EV,EV,,"['Copper depletion', 'Tetrathiomolybdate', 'Triple negative breast cancer', 'Metastasis', 'Mitochondrial metabolism', 'Oxidative phosphorylation', 'Complex IV', 'SOX2', 'OCT4', 'Cancer stem cells', 'AMPK', 'mTORC1', 'COX17', 'Copper chelation', 'Metabolic reprogramming']",,,,Keyword,protocolSection.conditionsModule.keywords,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.phases,TP,TP,['PHASE2'],['PHASE2'],True,1.0,exact,Phase,protocolSection.designModule.phases,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.allocation,TP,TP,NA,NA,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModel,TP,TP,SINGLE_GROUP,SINGLE_GROUP,True,1.0,exact,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModelDescription,EV,EV,,Phase II clinical trial of tetrathiomolybdate (TM) in high-risk breast cancer patients. The study evaluated TM as a copper chelating agent administered orally through drinking water.,,,,DesignInterventionModelDescription,protocolSection.designModule.designInfo.interventionModelDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.masking,TP,TP,NONE,NONE,True,1.0,exact,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.enrollmentInfo.count,TP,FP,16,75,False,0.2,success,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[2].label,EV,EV,,Trientine Treatment,,,,ArmGroupLabel,protocolSection.armsInterventionsModule.armGroups.label,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[3].label,EV,EV,,CTR1 Knockout,,,,ArmGroupLabel,protocolSection.armsInterventionsModule.armGroups.label,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[4].label,EV,EV,,COX17 Knockdown,,,,ArmGroupLabel,protocolSection.armsInterventionsModule.armGroups.label,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[5].label,EV,EV,,COX20 Knockdown,,,,ArmGroupLabel,protocolSection.armsInterventionsModule.armGroups.label,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[6].label,EV,EV,,AMPK Activation,,,,ArmGroupLabel,protocolSection.armsInterventionsModule.armGroups.label,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[7].label,EV,EV,,AMPK Inhibition,,,,ArmGroupLabel,protocolSection.armsInterventionsModule.armGroups.label,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[8].label,EV,EV,,Copper Add-back,,,,ArmGroupLabel,protocolSection.armsInterventionsModule.armGroups.label,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[2].type,EV,EV,,EXPERIMENTAL,,,,ArmGroupType,protocolSection.armsInterventionsModule.armGroups.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[3].type,EV,EV,,EXPERIMENTAL,,,,ArmGroupType,protocolSection.armsInterventionsModule.armGroups.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[4].type,EV,EV,,EXPERIMENTAL,,,,ArmGroupType,protocolSection.armsInterventionsModule.armGroups.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[5].type,EV,EV,,EXPERIMENTAL,,,,ArmGroupType,protocolSection.armsInterventionsModule.armGroups.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[6].type,EV,EV,,EXPERIMENTAL,,,,ArmGroupType,protocolSection.armsInterventionsModule.armGroups.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[7].type,EV,EV,,EXPERIMENTAL,,,,ArmGroupType,protocolSection.armsInterventionsModule.armGroups.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[8].type,EV,EV,,EXPERIMENTAL,,,,ArmGroupType,protocolSection.armsInterventionsModule.armGroups.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[2].description,EV,EV,,"Cells treated with trientine (50 µM), an independent copper chelator, to validate TM-mediated metabolic phenotypes",,,,ArmGroupDescription,protocolSection.armsInterventionsModule.armGroups.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[3].description,EV,EV,,Cells with CRISPR/Cas9-mediated knockout of copper transporter receptor 1 (CTR1) to achieve genetic model of global copper depletion,,,,ArmGroupDescription,protocolSection.armsInterventionsModule.armGroups.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[4].description,EV,EV,,Cells with shRNA-mediated knockdown of COX17 (mitochondrial copper chaperone) to restrict copper deficiency to mitochondria,,,,ArmGroupDescription,protocolSection.armsInterventionsModule.armGroups.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[5].description,EV,EV,,Cells with shRNA-mediated knockdown of COX20 (Complex IV assembly factor) to directly perturb Complex IV function,,,,ArmGroupDescription,protocolSection.armsInterventionsModule.armGroups.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[6].description,EV,EV,,Cells treated with pharmacological AMPK activators: AICAR (1.25 mM) or A-769662 (12.5 µM) to determine role of AMPK in invasion,,,,ArmGroupDescription,protocolSection.armsInterventionsModule.armGroups.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[7].description,EV,EV,,Cells transfected with siRNA against AMPK to determine if AMPK inhibition rescues TM-mediated loss of invasion,,,,ArmGroupDescription,protocolSection.armsInterventionsModule.armGroups.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[8].description,EV,EV,,Cells treated with TM plus copper supplementation (0.5 µM CuCl2) to rescue TM-mediated phenotypes,,,,ArmGroupDescription,protocolSection.armsInterventionsModule.armGroups.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[2].interventionNames,EV,EV,,['Drug: Trientine'],,,,ArmGroupInterventionName,protocolSection.armsInterventionsModule.armGroups.interventionNames,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[3].interventionNames,EV,EV,,['Genetic: CTR1 Knockout'],,,,ArmGroupInterventionName,protocolSection.armsInterventionsModule.armGroups.interventionNames,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[4].interventionNames,EV,EV,,['Genetic: COX17 Knockdown'],,,,ArmGroupInterventionName,protocolSection.armsInterventionsModule.armGroups.interventionNames,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[5].interventionNames,EV,EV,,['Genetic: COX20 Knockdown'],,,,ArmGroupInterventionName,protocolSection.armsInterventionsModule.armGroups.interventionNames,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[6].interventionNames,EV,EV,,"['Drug: AICAR', 'Drug: A-769662']",,,,ArmGroupInterventionName,protocolSection.armsInterventionsModule.armGroups.interventionNames,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[7].interventionNames,EV,EV,,['Genetic: siRNA AMPK'],,,,ArmGroupInterventionName,protocolSection.armsInterventionsModule.armGroups.interventionNames,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[8].interventionNames,EV,EV,,"['Drug: Tetrathiomolybdate (TM)', 'Dietary Supplement: Copper Chloride (CuCl2)']",,,,ArmGroupInterventionName,protocolSection.armsInterventionsModule.armGroups.interventionNames,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[1].type,EV,EV,,DRUG,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].type,EV,EV,,GENETIC,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].type,EV,EV,,GENETIC,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[4].type,EV,EV,,GENETIC,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[5].type,EV,EV,,DRUG,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[6].type,EV,EV,,DRUG,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[7].type,EV,EV,,GENETIC,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[8].type,EV,EV,,DIETARY_SUPPLEMENT,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[1].name,EV,EV,,Trientine,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].name,EV,EV,,CTR1 Knockout,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].name,EV,EV,,COX17 Knockdown,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[4].name,EV,EV,,COX20 Knockdown,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[5].name,EV,EV,,AICAR,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[6].name,EV,EV,,A-769662,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[7].name,EV,EV,,siRNA AMPK,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[8].name,EV,EV,,Copper Chloride (CuCl2),,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[1].description,EV,EV,,Independent copper chelator used at 50 µM in cell culture to validate TM-mediated metabolic phenotypes,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].description,EV,EV,,CRISPR/Cas9-mediated knockout of copper transporter receptor 1 (CTR1) using guide sequence TTGGTGATCAATACAGCTGG to create genetic model of global copper depletion,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].description,EV,EV,,Lentiviral shRNA-mediated knockdown of cytochrome c oxidase 17 (COX17) using hairpins TRCN0000046062 and TRCN0000046060 to restrict copper delivery to mitochondria,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[4].description,EV,EV,,"Lentiviral shRNA-mediated knockdown of COX20 (TRCN0000339218), a Complex IV assembly factor, to directly perturb Complex IV function",,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[5].description,EV,EV,,Pharmacological AMPK activator (adenosine analogue 5-aminoimidazole-4-carboxamide riboside) used at 1.25 mM to activate AMPK and assess impact on invasion,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[6].description,EV,EV,,Pharmacological AMPK activator used at 12.5 µM to activate AMPK and assess impact on invasion,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[7].description,EV,EV,,siRNA-mediated knockdown of AMPK (10 nM) to determine if AMPK inhibition rescues TM-mediated loss of invasion phenotype,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[8].description,EV,EV,,Copper supplementation at 0.5 µM added to TM-treated cells to rescue copper depletion-mediated phenotypes including invasion and oxygen consumption,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[1].armGroupLabels,EV,EV,,['Trientine Treatment'],,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].armGroupLabels,EV,EV,,['CTR1 Knockout'],,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].armGroupLabels,EV,EV,,['COX17 Knockdown'],,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[4].armGroupLabels,EV,EV,,['COX20 Knockdown'],,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[5].armGroupLabels,EV,EV,,['AMPK Activation'],,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[6].armGroupLabels,EV,EV,,['AMPK Activation'],,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[7].armGroupLabels,EV,EV,,['AMPK Inhibition'],,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[8].armGroupLabels,EV,EV,,['Copper Add-back'],,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.primaryOutcomes[1].measure,EV,EV,,Lung metastatic burden in preclinical models,,,,PrimaryOutcomeMeasure,protocolSection.outcomesModule.primaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.primaryOutcomes[0].description,EV,EV,,EFS was measured as the time from treatment initiation to disease relapse or death. The study reported EFS of 59.3% for stage 4 NED TNBC patients at median follow-up of 9.4 years.,,,,PrimaryOutcomeDescription,protocolSection.outcomesModule.primaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.primaryOutcomes[1].description,EV,EV,,Metastatic burden was assessed by bioluminescence imaging (BLI) of lungs 2 weeks after primary tumor resection in orthotopic mouse models (LM2 and ML1).,,,,PrimaryOutcomeDescription,protocolSection.outcomesModule.primaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.primaryOutcomes[1].timeFrame,EV,EV,,2 weeks after primary tumor resection,,,,PrimaryOutcomeTimeFrame,protocolSection.outcomesModule.primaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[0].measure,EV,EV,,Overall survival (OS) in breast cancer patients,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[1].measure,EV,EV,,Primary tumor growth,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[2].measure,EV,EV,,Cell invasion capacity,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[3].measure,EV,EV,,Intracellular copper levels,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[4].measure,EV,EV,,Ceruloplasmin levels,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[0].description,EV,EV,,OS was measured from treatment initiation to death from any cause. The phase II trial reported OS of 84% at median follow-up of 6.3 years.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[1].description,EV,EV,,Primary tumor volume was measured using calipers in orthotopic mouse models to assess the effect of TM on tumor growth.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[2].description,EV,EV,,"Invasion was assessed using Matrigel-coated transwell assays, measuring the number of cells that migrated through the matrix over 24 hours.",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[3].description,EV,EV,,Copper content was measured using graphite furnace atomic absorption spectrometry (GFAAS) to assess copper depletion following TM treatment.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[4].description,EV,EV,,"Serum ceruloplasmin, a copper-carrying protein, was measured to confirm systemic copper depletion in TM-treated mice.",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[0].timeFrame,EV,EV,,Median follow-up of 6.3 years,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[1].timeFrame,EV,EV,,Up to 4 weeks or until tumors reached 1 cm³,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[2].timeFrame,EV,EV,,24 hours after plating on transwell inserts,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[3].timeFrame,EV,EV,,24-72 hours after TM treatment,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[4].timeFrame,EV,EV,,2 weeks after TM administration,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].measure,EV,EV,,Mitochondrial Complex IV activity,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[1].measure,EV,EV,,Oxygen consumption rate (OCR),,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[2].measure,EV,EV,,SOX2/OCT4+ cell population frequency,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[3].measure,EV,EV,,AMPK activation,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[4].measure,EV,EV,,Disseminated tumor cells in lungs,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[5].measure,EV,EV,,Mitochondrial cristae morphology,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[6].measure,EV,EV,,Glucose consumption and lactate production,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[7].measure,EV,EV,,Mitochondrial ATP production rate,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].description,EV,EV,,Complex IV enzyme activity was measured using a cytochrome c oxidase activity assay to assess the impact of copper depletion on mitochondrial function.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[1].description,EV,EV,,"OCR was measured using Seahorse XF bioanalyzer to assess mitochondrial respiration, including basal respiration and ATP-linked respiration.",,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[2].description,EV,EV,,The percentage of SOX2/OCT4+ GFP+ cells in primary tumors was quantified by flow cytometry to assess the effect of TM on metastatic cell populations.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[3].description,EV,EV,,Phosphorylation of AMPK at Thr172 was assessed by Western blot to determine activation of the AMPK energy sensor pathway following TM treatment.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[4].description,EV,EV,,The number of mCherry+ tumor cells in early lungs (without overt metastatic outgrowth) was quantified by flow cytometry to assess early dissemination.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[5].description,EV,EV,,"Cristae structure was assessed by transmission electron microscopy, quantifying the number of perturbed cristae per mitochondrial area.",,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[6].description,EV,EV,,Glucose and lactate levels in cell culture supernatants were measured to assess metabolic reprogramming following TM treatment.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[7].description,EV,EV,,The ratio of mitochondrial to glycolytic ATP production was measured using Seahorse ATP production rate assay.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].timeFrame,EV,EV,,72 hours after TM treatment,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[1].timeFrame,EV,EV,,48-72 hours after TM treatment,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[2].timeFrame,EV,EV,,At primary tumor harvest (4-6 weeks after tumor implantation),,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[3].timeFrame,EV,EV,,48-72 hours after TM treatment,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[4].timeFrame,EV,EV,,At the time of primary tumor resection,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[5].timeFrame,EV,EV,,72 hours after TM treatment,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[6].timeFrame,EV,EV,,72 hours after TM treatment,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[7].timeFrame,EV,EV,,48-72 hours after TM treatment,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.eligibilityCriteria,TP,FP,"Inclusion Criteria:

1. Patients must have histologically confirmed breast malignancy that is:

   * High risk stage II breast cancer (≥4 positive lymph nodes),
   * Stage III breast cancer, including inflammatory breast cancer
   * Stage IV breast cancer in a complete remission (bone only not allowed unless the bone scan is normal).
2. The patient must have had what is considered standard adjuvant systemic therapy that may include chemotherapy, hormonal therapy and radiation therapy. They may have undergone high dose chemotherapy with stem cell support as part of their therapy in the adjuvant or metastatic setting. The patient is allowed to continue to take adjuvant hormonal therapy (for high risk adjuvant patients) and may be allowed to be on hormonal consolidation post transplant if they are without evidence of disease after a transplant for metastatic breast cancer. The patient cannot be actively receiving chemotherapy or any biologic agent to treat their breast cancer.
3. Six weeks must elapse from last chemotherapy or radiation therapy.
4. The patient must have had definitive surgical therapy for their breast cancer. This includes lumpectomy and axillary dissection or mastectomy.
5. No clinical or radiologic evidence of disease after surgery and/or systemic treatment (by CT scan of chest, abdomen and pelvis and bone scan or PET scan prior to enrollment)
6. Because no dosing or adverse event data are currently available on the use of TM in patients \< 18 years of age, children are excluded from this study.
7. ECOG performance status \< 1
8. Life expectancy of greater than 3 months.
9. Patients must have normal organ and marrow function as defined below:

   * hemoglobin \>10mg/dL
   * absolute neutrophil count \>1,500/mL
   * platelets \>100,000/mL
   * total bilirubin \< 1.5 x normal institutional limits
   * AST(SGOT)/ALT(SGPT) \<1.5 X institutional upper limit of normal
10. Erythropoietin alpha is allowed, as indicated.
11. Bisphosphonates may be administered if they were started prior to starting this therapy.
12. Patients must be on stable medical therapy for at least 2 weeks if they are being treated medically for their peripheral neuropathy.
13. Concurrent herceptin is not allowed.
14. The effects of TM on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
15. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Patients who have had chemotherapy or radiotherapy within 6 weeks prior to entering the study.
2. Objective evidence of breast cancer.
3. Carcinomatous meningitis or history of neoplastic parenchymal brain disease.
4. Serum creatinine \>1.5 x normal.
5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to TM.
6. Pregnant women are excluded from this study because TM has the potential to have teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with TM, breastfeeding should be discontinued if the mother is treated with TM.
7. Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with TM.","Not explicitly provided in the paper content. The paper describes preclinical research using cell lines and mouse models, not a clinical trial with human participant eligibility criteria.",False,0.08,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,False,False,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.sex,TP,FP,FEMALE,ALL,False,0.5,success,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.minimumAge,TP,FP,18 Years,N/A,False,0.08,success,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.maximumAge,EV,EV,,N/A,,,,MaximumAge,protocolSection.eligibilityModule.maximumAge,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.stdAges,FN,FN,"['ADULT', 'OLDER_ADULT']",,False,0.0,,StdAge,protocolSection.eligibilityModule.stdAges,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.studyPopulation,EV,EV,,"Not applicable - this is a preclinical study using cell lines (MDA-MB-231-LM2, EO771.ML1) and mouse models (C57Bl/6j mice, SCID mice)",,,,StudyPopulation,protocolSection.eligibilityModule.studyPopulation,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.samplingMethod,EV,EV,,NON_PROBABILITY_SAMPLE,,,,SamplingMethod,protocolSection.eligibilityModule.samplingMethod,True,False,True,False,False,False
